Top

Published in:

01-06-2009

Concordant colon tumors in monozygotic twins previously treated for prostate cancer

Authors: Arnoud Templeton, Giancarlo Marra, Emanuele Valtorta, Karl Heinimann, Hansjakob Müller, Dieter Köberle, Silke Gillessen

Published in: Familial Cancer | Issue 2/2009

Abstract

This report describes the quasi-simultaneous occurrence of colon cancers in monozygotic twin brothers (age 63 years) who had undergone androgen deprivation therapy for prostate cancers 4 years earlier. Concordance among male twins for both of these cancers has never been reported. Although the family history suggested possible genetic predispositions to both cancers, the twins have no evidence of the genetic alterations associated with hereditary colorectal tumors. We explore the possibility that colorectal tumorigenesis in these twins was fuelled by a combination of genetic and iatrogenic factors, in particular the androgen deprivation therapy used to treat their prostate cancers.

Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85. doi:10.1056/NEJM200007133430201 PubMedCrossRef

Schaid DJ (2004) The complex genetic epidemiology of prostate cancer. Hum Mol Genet 13(Spec No 1):R103–R121PubMedCrossRef

Vasen HF (2000) Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol 18:81S–92SPubMed

Edwards SM, Eeles RA (2004) Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet 129:65–73. doi:10.1002/ajmg.c.30027 CrossRef

Steinberg GD, Carter BS, Beaty TH et al (1990) Family history and the risk of prostate cancer. Prostate 17:337–347. doi:10.1002/pros.2990170409 PubMedCrossRef

Johns LE, Houlston RS (2003) A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 91:789–794. doi:10.1046/j.1464-410X.2003.04232.x PubMedCrossRef

Gronberg H, Damber L, Damber JE (1994) Studies of genetic factors in prostate cancer in a twin population. J Urol 152:1484–1487PubMed

Page WF, Braun MM, Partin AW et al (1997) Heredity and prostate cancer: a study of World War II veteran twins. Prostate 33:240–245. doi:10.1002/(SICI)1097-0045(19971201)33:4<240::AID-PROS3>3.0.CO;2-LPubMedCrossRef

Cybulski C, Gorski B, Huzarski T et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131–1135. doi:10.1086/426403 PubMedCrossRef

10.

Lichtenstein P, Sullivan PF, Cnattingius S et al (2006) The Swedish Twin registry in the third millennium: an update. Twin Res Hum Genet 9:875–882. doi:10.1375/twin.9.6.875 PubMedCrossRef

11.

Nelson WG, De Marzo AM, Isaacs WB (2003) Prostate cancer. N Engl J Med 349:366–381. doi:10.1056/NEJMra021562 PubMedCrossRef

12.

Gelmann EP (2008) Complexities of prostate-cancer risk. N Engl J Med 358:961–963. doi:10.1056/NEJMe0708703 PubMedCrossRef

13.

Truninger K, Menigatti M, Luz J et al (2005) Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 128:1160–1171. doi:10.1053/j.gastro.2005.01.056 PubMedCrossRef

14.

Catalano MG, Pfeffer U, Raineri M et al (2000) Altered expression of androgen-receptor isoforms in human colon-cancer tissues. Int J Cancer 86:325–330. doi:10.1002/(SICI)1097-0215(20000501)86:3<325::AID-IJC4>3.0.CO;2-GPubMedCrossRef

15.

Pereira MA, Khoury MD (1991) Prevention by chemopreventive agents of azoxymethane-induced foci of aberrant crypts in rat colon. Cancer Lett 61:27–33. doi:10.1016/0304-3835(91)90073-Q PubMedCrossRef

16.

Rao CV, Tokumo K, Rigotty J et al (1991) Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 51:4528–4534PubMed

17.

Stebbings WS, Vinson GP, Farthing MJ et al (1989) Effect of steroid hormones on human colorectal adenocarcinoma xenografts, of known steroid-receptor status, in nude mice. J Cancer Res Clin Oncol 115:439–444. doi:10.1007/BF00393333 PubMedCrossRef

18.

Aoki K, Nakajima A, Mukasa K et al (2003) Prevention of diabetes, hepatic injury, and colon cancer with dehydroepiandrosterone. J Steroid Biochem Mol Biol 85:469–472. doi:10.1016/S0960-0760(03)00219-X PubMedCrossRef

19.

Izbicki JR, Hamilton SR, Wambach G et al (1990) Effects of androgen manipulations on chemically induced colonic tumours and on macroscopically normal colonic mucosa in male Sprague-Dawley rats. Br J Cancer 61:235–240PubMed

20.

Chesire DR, Isaacs WB (2002) Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. Oncogene 21:8453–8469. doi:10.1038/sj.onc.1206049 PubMedCrossRef

21.

Mulholland DJ, Read JT, Rennie PS et al (2003) Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Oncogene 22:5602–5613. doi:10.1038/sj.onc.1206802 PubMedCrossRef

22.

Chen SY, Wulf G, Zhou XZ et al (2006) Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction. Mol Cell Biol 26:929–939. doi:10.1128/MCB.26.3.929-939.2006 PubMedCrossRef

23.

Van der Flier LG, Sabates-Bellver J, Oving I et al (2007) The intestinal Wnt/TCF signature. Gastroenterology 132:628–632. doi:10.1053/j.gastro.2006.08.039 PubMedCrossRef

Title: Concordant colon tumors in monozygotic twins previously treated for prostate cancer
Authors: Arnoud Templeton
Giancarlo Marra
Emanuele Valtorta
Karl Heinimann
Hansjakob Müller
Dieter Köberle
Silke Gillessen
Publication date: 01-06-2009
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 2/2009
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-008-9222-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women

Intussusception in the adult: an unsuspected case of Peutz–Jeghers syndrome with review of the literature

Factors associated with intrusive cancer-related worries in women undergoing cancer genetic risk assessment

Familial nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in screening

Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis

Analysis of BRCA1/BRCA2 genes’ contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women

Keynote webinar | Spotlight on antibody–drug conjugates in cancer